Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.34 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.30 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.30 |
| ▸ | CKS1B | P61024 | 1/20 | 0.30 |
| ▸ | SKP1 | P63208 | 1/20 | 0.30 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31032340 | 1.00 | MEN1 (0.40) | MEN1KMT2AKDM4ESTING1TDP1 | |
| SCHEMBL31032310 | 1.00 | MEN1 (0.40) | MEN1KMT2AKDM4ESTING1TDP1 | |
| SCHEMBL31032358 | 1.00 | MEN1 (0.40) | MEN1KMT2AKDM4ESTING1TDP1 | |
| SCHEMBL31032354 | 0.99 | MEN1 (0.40) | MEN1KMT2AKDM4ESTING1CSNK2A2 | |
| SCHEMBL3409879 | 0.81 | MEN1 (0.47) | MEN1KMT2AALDH1A1 | |
| SCHEMBL31032348 | 0.80 | KMT2A (0.49) | MEN1KMT2AKDM4ETDP1ALDH1A1 | |
| SCHEMBL31032333 | 0.80 | KMT2A (0.49) | MEN1KMT2AKDM4ETDP1ALDH1A1 | |
| SCHEMBL31032265 | 0.78 | KMT2A (0.50) | MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL18059176 | 0.70 | CA12 (0.40) | MEN1KMT2AKDM4ESTING1TDP1 | |
| SCHEMBL31524058 | 0.70 | CA12 (0.40) | MEN1KMT2AKDM4ESTING1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240287033-A1 | DEGRADERS OF TISSUE TRANSGLUTAMINASE 2 (TG2) | UNITED STATES GOVERNMENT | 2024-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287033-A1 | DEGRADERS OF TISSUE TRANSGLUTAMINASE 2 (TG2) | PSMG3, UBE2G2, UBE2L3 | MEN1 606/4885KMT2A 240/4885KDM4E 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.